FDA Approves Actavis (ACT) SAPHRIS sNDA
Tweet Send to a Friend
Actavis (NYSE: ACT) announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


